(Q35217836)

7 August 2017

1 reference

title

Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection (English)

1 reference

7 August 2017

main subject

liver transplantation

1 reference

Federico G Villamil

1

1 reference

7 August 2017

publication date

1 October 2003

1 reference

7 August 2017

published in

Journal of Hepatology

1 reference

7 August 2017

volume

39

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

466-474

1 reference

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Liver transplantation in hepatitis B patients with preoperative resistance formation during lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Retransplantation of patients with severe posttransplant hepatitis B in the first allograft

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

Hepatitis B vaccination after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900396-9

7 January 2021

10.1016/S0168-8278(03)00396-9

Identifiers

DOI

1 reference

7 August 2017

1 reference